Selective alterations of the antibody response to HIV-1

被引:0
|
作者
Laure Juompan
Patrick Lambin
Moncef Zouau
机构
[1] Institut Pasteur,Département d’Immunologie
[2] Unité d’Immunologie Transfusionelle,undefined
来源
Applied Biochemistry and Biotechnology | 1998年 / 75卷
关键词
Superantigen; gpl20; HIV; B-cell; human antibodies; immunoglobulin variable genes; isotypes; mucosal antibodies;
D O I
暂无
中图分类号
学科分类号
摘要
HIV infection leads to progressive alterations of humoral immune functions, including B-cell hyperplasia, hypergammaglobulinemia, elevated autoantibody titers, a poor response to neoantigens and mitogens, polyclonal B-cell activation, monoclonal gammopathies, and a significant deterioration of the antigen-specific humoral response. There is also an important isotypic imbalance of the antibody (Ab) response in the systemic compartment and a profound modification of mucosal immune functions. These abnormalities may contribute to disease progression and development of opportunistic infections, despite the presence of serum-neutralizing anti-HIV Abs. Equally important are the abnormal selection mechanisms of the Ab repertoire that seem to be responsible for B-cell clonal deletions. The VH3 gene family, which encodes for approx 50% of immunoglobulins expressed by peripheral B-cells from normal adults, is underrepresented in human monoclonal antibodies to HIV-1 and in the peripheral B-cells of AIDS patients. These abnormalities, together with features of germinal center alteration, could be responsible for the clonal elimination of a subset of B-cells, and could contribute to HIV pathogenesis.
引用
收藏
页码:139 / 150
页数:11
相关论文
共 50 条
  • [11] The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity
    Parren, PWHI
    Moore, JP
    Burton, DR
    Sattentau, QJ
    AIDS, 1999, 13 : S137 - S162
  • [12] COGNITIVE ALTERATIONS ASSOCIATED WITH HIV-1 INFECTION AND AIDS
    Christo, Paulo Pereira
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2010, 56 (02): : 242 - 247
  • [13] HIV-1 and the immune response to TB
    Walker, Naomi F.
    Meintjes, Graeme
    Wilkinson, Robert J.
    FUTURE VIROLOGY, 2013, 8 (01) : 57 - 80
  • [14] Broadly neutralizing HIV-1 antibody reactivity in HIV tests: implications for diagnostics
    Smith, Tara
    Masciotra, Silvina
    Luo, Wei
    Sullivan, Vickie
    Switzer, William M.
    Johnson, Jeffrey A.
    Heneine, Walid
    AIDS, 2021, 35 (10) : 1561 - 1565
  • [15] Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women
    Mkhize, Nonhlanhla N.
    Durgiah, Raveshni
    Ashley, Vicki
    Archary, Derseree
    Garrett, Nigel J.
    Karim, Quarraisha Abdool
    Karim, Salim S. Abdool
    Moore, Penny L.
    Yates, Nicole
    Passmore, Jo-Ann S.
    Tomaras, Georgia D.
    Morris, Lynn
    AIDS, 2016, 30 (07) : 1005 - 1014
  • [16] Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection
    Chahine, Elias B.
    Durham, Spencer H.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (02) : 230 - 239
  • [17] OraQuick® ADVANCE rapid HIV-1/2 antibody test
    Reynolds, SJ
    Muwonga, J
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2004, 4 (05) : 587 - 591
  • [18] Current methods for detecting and assessing HIV-1 antibody resistance
    Odidika, Stanley
    Pirkl, Martin
    Lengauer, Thomas
    Schommers, Philipp
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [19] Selective inhibition of HIV-1 reverse transcriptase (HIV-1 RT) RNase H by small RNA hairpins and dumbbells
    Hannoush, RN
    Carriero, S
    Min, KL
    Damha, MJ
    CHEMBIOCHEM, 2004, 5 (04) : 527 - 533
  • [20] COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research
    Mendoza, Pilar
    Lorenzi, Julio C. C.
    Gaebler, Christian
    CURRENT OPINION IN HIV AND AIDS, 2021, 16 (01) : 25 - 35